Join BMO and industry leaders in New York on March 25 for the BMO 2025 Obesity Summit to discuss the growing $150 billion obesity therapies market. The Summit features an exciting line-up of leaders ...

While President Trump is currently shaking international norms, there is one area where his challenge to global institutions is profoundly good: ending America’s acquiescence to the Organisation ...

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk of diabetic retinopathy THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 ...

THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...

“Yes, I am on a GLP-1, or a weight loss medication." "Now, if you have been following me for a long time, you’ll know that I’ve gained and lost weight several times very publicly," they ...

I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

ORLANDO, FLA. — What the full impact of GLP-1 medications will be on food and beverage consumption patterns is impossible to know. Use of the medications today is limited and there is much to ...

Data from the yellow card scheme for reporting adverse events to the Medicines and Healthcare Products Regulatory Agency (MHRA) show that up to 31 January 2025 there were 22 deaths from adverse ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...